CCL

Összesen 22 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM015794
Első szerző:Arnson, Yoav
Cím:Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis a retrospective cohort study and review of the literature / Yoav Arnson, Howard Amital, Nancy Agmon-Levin, Danny Alon, María Sánchez-Castanón, Marcos López-Hoyos, Marco Matucci-Cerinic, Gabriella Szücs, Yinon Shapira, Zoltan Szekanecz, Yehuda Shoenfeld
Dátum:2011
ISSN:1568-9972
Megjegyzések:Low vitamin D serum concentrations have been reported in several autoimmune conditions. The study's aim was to explore such a relationship in a large multinational population of patients with systemic sclerosis (SSc) and to pursue possible clinical and laboratory correlates with vitamin D concentrations. 327 sera samples of European patients with SSc and 141 samples of compatible healthy controls were studied for vitamin D concentrations using the commercial kit LIAISON 25-OH vitamin D assay (Diasorin). Additionally, clinical parameters including the Rodnan skin score, diffusing lung capacity for carbon monoxide (DLCO), systolic pulmonary artery pressure (sPAP), forced vital capacity (FVC), and nailfold video capillaroscopic, erythrocyte sedimentation rate (ESR), anti-nuclear antibodies (ANA and scl70), rheumatoid factor (RF) were investigated. Vitamin D serum concentration was 13.5+/-9.0ng/ml (mean+/-standard deviation) in patients with SSc compared to 21.6+/-9.7ng/ml in a control group (p<0.001). A negative correlation between patients' age and vitamin D concentration (r=-0.2, p<0.05, n=96) was observed. An inverse relationship was found between skin involvement and vitamin D serum concentrations; Patients with a Rodnan skin score of 10 or lower (n=11) had a mean vitamin D concentration of 17.7+/-10.4ng/ml compared to patients with a score above 10 (n=28) 8+/-10.1ng/ml (p=0.02, by the Mann-Whitney test). In conclusion, Patients with SSc have significantly lower serum vitamin D concentrations compared to healthy controls; moreover fibrosis of the cutaneous tissue is inversely related to the vitamin D concentration.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Autoimmunity Reviews. - 10 : 8 (2011), p. 490-494. -
További szerzők:Amital, Howard Agmon-Levin, Nancy Alon, Danny Sánchez-Castanón, María Lopez-Hoyos, Marcos Matucci-Cerinic, Marco Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Shapira, Yinon Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Shoenfeld, Yehuda
Internet cím:DOI
elektronikus változat
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM114387
Első szerző:Caporali, Roberto
Cím:Start RA Treatment - Biologics or JAK-Inhibitors? / Roberto Caporali, Sabino Germinario, Dorottya Kacsándi, Ernest Choy, Zoltán Szekanecz
Dátum:2023
ISSN:1568-9972
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Autoimmunity Reviews. - [Epub ahead of print] (2023). -
További szerzők:Germinario, Sabino Kacsándi Dorottya Choy, Ernest Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
http://dx.doi.org/
Borító:

3.

001-es BibID:BIBFORM035127
Első szerző:Doria, Andrea
Cím:Controversies in rheumatism and autoimmunity / Andrea Doria, Chaim Putterman, Piercarlo Sarzi-Puttini, Zoltán Szekanecz, Yehuda Shoenfeld
Dátum:2012
ISSN:1568-9972
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
rheumatism
autoimmunity
arthritis
endothelíal dysfunction
biologics
külföldön készült közlemény
Megjelenés:Autoimmunity Reviews. - 11 : 8 (2012), p. 555-557. -
További szerzők:Putterman, Chaim Sarzi-Puttini, Piercarlo Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Shoenfeld, Yehuda
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM067428
Első szerző:Elshabrawy, Hatem A.
Cím:TLRs, future potential therapeutic targets for RA / Hatem A. Elshabrawy, Abdul E. Essani, Zoltán Szekanecz, David A. Fox, Shiva Shahrara
Dátum:2017
ISSN:1568-9972
Megjegyzések:Toll like receptors (TLR)s have a central role in regulating innate immunity and in the last decade studies have begun to reveal their significance in potentiating autoimmune diseases such as rheumatoid arthritis (RA). Earlier investigations have highlighted the importance of TLR2 and TLR4 function in RA pathogenesis. In this review, we discuss the newer data that indicate roles for TLR5 and TLR7 in RA and its preclinical models. We evaluate the pathogenicity of TLRs in RA myeloid cells, synovial tissue fibroblasts, T cells, osteoclast progenitor cells and endothelial cells. These observations establish that ligation of TLRs can transform RA myeloid cells into M1 macrophages and that the inflammatory factors secreted from M1 and RA synovial tissue fibroblasts participate in TH-17 cell development. From the investigations conducted in RA preclinical models, we conclude that TLR-mediated inflammation can result in osteoclastic bone erosion by interconnecting the myeloid and TH-17 cell response to joint vascularization. In light of emerging unique aspects of TLR function, we summarize the novel approaches that are being tested to impair TLR activation in RA patients.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Rheumatoid arthritis (RA)
Toll like receptors (TLR)s
Inflammation
Bone erosion
M1 macrophages
TH-17 cells
Megjelenés:Autoimmunity Reviews 16 : 2 (2017), p. 103-113. -
További szerzők:Essani, Abdul E. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Fox, David A. Shahrara, Shiva
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM082169
035-os BibID:(PMID)31733368 (cikkazonosító)102421
Első szerző:Favalli, Ennio Giulio
Cím:The Giants (biologicals) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis / Ennio Giulio Favalli, Marco Matucci-Cerinic, Zoltan Szekanecz
Dátum:2020
ISSN:1568-9972
Megjegyzések:Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that, if untreated, can lead to disability and reduce the life expectancy of affected patients. Over the last two decades the improvement of knowledge of the pathogenetic mechanisms leading to the development of the disease has profoundly changed the treatment strategies of RA through the development of biotechnological drugs (bDMARDs) directed towards specific proinflammatory targets involved in the RA network. To date, the therapeutic armamentarium for RA includes ten bDMARDs able to produce the depletion B-cells, the blockade of three different pro-inflammatory cytokines (tumour necrosis factor alpha, interleukin-6 and interleukin-1), or the inhibition of T-cell co-stimulation. The introduction of these new compounds has dramatically improved outcomes in the short and long term, although still a significant proportion of patients are unable to reach or maintain the treatment target over time. The identification of the fundamental role of Janus kinases in the process of transduction of the inflammatory signal within the immune cells has recently provided the opportunity to use the new pharmacological class of small molecules for the therapy of RA, further increasing the number of treatment options. In this review the PROS and CONS of these two drug classes will be discussed, trying to provide the evidence currently available to make the right choice based on the analysis of the efficacy and safety profile of the different drugs on the market and close to marketing.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Biologic agents
Efficacy
JAK inhibitors
Personalised medicine
Rheumatoid arthritis
Safety profile
Megjelenés:Autoimmunity Reviews. - 19 : 1 (2020), p. 1-8. -
További szerzők:Matucci-Cerinic, Marco Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM092833
Első szerző:Frantz, Camelia
Cím:Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database / Camelia Frantz, Dorte Huscher, Jérôme Avouac, Eric Hachulla, Alexandra Balbir-Gurman, Gabriela Riemekasten, Elise Siegert, Maria-Grazia Lazzaroni, Patricia E. Carreira, Serena Vettori, Elisabetta Zanatta, Susanne Ullman, Laszlo Czirjàk, Otylia Kowal-Bielecka, Oliver Distler, Marco Matucci-Cerinic, Yannick Allanore, EUSTAR
Dátum:2020
ISSN:1568-9972
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Autoimmunity Reviews. - 19 : 2 (2020), p. 1-7. -
További szerzők:Huscher, Dörte Avouac, Jérôme Hachulla, Eric Balbir Gurman, Alexandra Riemekasten, Gabriela Siegert, Elise Lazzaroni, Maria-Grazia Carreira, Patricia E. Vettori, Serena Zanatta, Elisabetta Ullman, Susanne Czirják László Kowal-Bielecka, Otylia Distler, Oliver Matucci-Cerinic, Marco Allanore, Yannick Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) EUSTAR
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM007068
Első szerző:Karosi Tamás (fül-orr-gégész)
Cím:Otosclerosis : an autoimmune disease? / Karosi, T., Szekanecz, Z., Sziklai, I.
Dátum:2009
ISSN:1873-0183 (Electronic)
Megjegyzések:To review our current knowledge of the etiopathogenesis of otosclerotic bone remodeling including genetics, viral infection, autoimmunity and inflammation and to discuss disease pathogenesis with relevance for pharmacotherapy. SYSTEMATIC REVIEW METHODOLOGY: Relevant publications on the etiopathogenesis, molecular biology, genetics and histopathology of otosclerosis from 1984 to 2009 were analyzed. RESULTS AND CONCLUSIONS: Otosclerosis is a bone remodeling disorder of the human otic capsule, however, the etiopathogenesis remains unclear. Genetic predisposition, disturbed bone metabolism, persistent measles virus infection, autoimmunity, hormonal and environmental factors also may play contributing roles in the pathogenesis of otosclerosis. Since, diagnosis of otosclerosis is still based on histopathological examination of the removed stapes footplate, systemic prospective studies based on comprehensive histopathological and molecular biological analysis are necessary to get further information about the background of disease.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Autoimmunity Reviews. - 9 : 2 (2009), p. 95-101. -
További szerzők:Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Sziklai István (1954-) (fül-orr-gégész)
Internet cím:elektronikus változat
DOI
elektronikus változat
Borító:

8.

001-es BibID:BIBFORM109481
035-os BibID:(cikkazonosító)103311 (Scopus)85150926379 (WoS)000951636500001
Első szerző:Mogyoróssy Sándor
Cím:Novel aspects of muscle involvement in immune-mediated inflammatory arthropathies and connective tissue diseases / Mogyoróssy Sándor, Nagy-Vincze Melinda, Griger Zoltán, Dankó Katalin, Szabó Nóra Anna, Szekanecz Zoltán, Szűcs Gabriella, Szántó Antónia, Bodoki Levente
Dátum:2023
ISSN:1568-9972
Megjegyzések:Myalgia, myopathy and myositis are the most important types of muscle impairment in immune-mediated inflammatory arthropathies and connective tissue diseases. Multiple pathogenetic and histological changes occur in the striated muscles of these patients. Clinically, the most important muscle involvement is the one that causes complaints to the patients. In everyday practice, insidious symptoms present a serious problem for the clinician; in many cases, it is difficult to decide when and how to treat the muscle symptoms that are often present only subclinically. In this work, authors review the international literature on the types of muscle problems in autoimmune diseases. In scleroderma histopathological picture of muscle shows a very heterogeneous picture, necrosis and atrophy are common. In rheumatoid arthritis and systemic lupus erythematosus, myopathy is a much less defined concept, further studies are needed to describe it. According to our view, overlap myositis should be recognized as a separate entity, preferably with distinct histological and serological characteristics. More studies are needed to describe muscle impairment in autoimmune diseases which may help to explore this topic more in depth and be of clinical use.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Myalgia
Myopathy
Myositis
Rheumatoid arthritis
Systemic sclerosis
Systemic lupus erythematosus
Megjelenés:Autoimmunity Reviews. - 22 : 5 (2023), p. 1-7. -
További szerzők:Nagy-Vincze Melinda (1985-) (orvos) Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Szabó Nóra Anna (1976-) (orvos) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Szántó Antónia (1977-) (belgyógyász, allergológus és klinikai immunológus) Bodoki Levente (1986-) (PhD hallgató)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

9.

001-es BibID:BIBFORM033045
Első szerző:Nakken, Britt
Cím:B-cells and their targeting in rheumatoid arthritis : current concepts and future perspectives / Nakken B., Munthe L. A., Konttinen Y. T., K. Sandberg A., Szekanecz Z., Alex P., Szodoray P.
Dátum:2011
ISSN:1568-9972
Megjegyzések:Rheumatoid arthritis (RA) is a chronic, autoimmune disease that affects primarily the joints and without proper treatment results in their progressive destruction. In addition to T-cells, B-cells play a central role in the pathogenesis of this disease. The synovial tissue is an active site of B-cell accumulation, plasma cell differentiation and in situ antibody-production in RA. As part of the complex role of B-cells in the joints and synovial membrane of RA patients, B cells secrete chemokines and cytokines and may function as antigen presenting cells. The multifaceted pathogenic function of B-cells identifies them as excellent targets for immunosuppressive therapy. B-cell targeting involves a wide spectrum of molecules, for example the B-cell antigen CD20 that allows specific and effective B-cell depletion. Another target, CD79, expressed by B-cell and plasma cell precursors is an obvious candidate that induces apoptosis as well as inhibition of B-cell receptor (BCR) activation and possibly depletion of ectopic germinal centers (GC). Inhibition of B-cell co-stimulatory molecules such as CD40, CD80/86 and ICOS, can lead to diminished B-cell activation. Moreover, anti-chemokine and anti-cytokine therapies can be efficacious in RA by the disruption of B-cell activation and autoantibody production. B-cell synovial migration and ectopic GC formation. Finally, targeting the signal transduction pathways required for proximal BCR signaling has also been found efficacious in early clinical trials in RA. Even so, some B cells inhibit immune responses, these regulatory B cells may play a part in immune regulation in patients and it is unclear what effects B cell depletion strategies have in terms of such B cell subsets. This review discusses current strategies of targeting B-cells as therapeutic candidates in the management of RA. Better insights into the pathogenic role of B-cells provide efficacious opportunities to improve both therapy and prognosis of patients with RA.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Autoimmunity Reviews. - 11 : 1 (2011), p. 28-34. -
További szerzők:Munthe, Ludvig A. Konttinen, Yrjö T. Klokk Sandberg, Anna Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Alex, Philip Szodoray Péter (1973-) (belgyógyász, orvos)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

10.

001-es BibID:BIBFORM081581
Első szerző:Sarzi-Puttini, Piercarlo
Cím:Biosimilars vs originators : are they the same? / Sarzi-Puttini Piercarlo, Marotto Daniela, Caporali Roberto, Galeazzi Mauro, Atzeni Fabiola, Hamar Attila, Soós Boglárka, Szekanecz Zoltán
Dátum:2019
ISSN:1568-9972
Megjegyzések:Biological drugs have revolutionised the treatment of rheumatic diseases, and the recent expiry of the patents for many biological agents has generated considerable interest among pharmaceutical companies and regulatory agencies, and led to the marketing of highly similar, low-cost versions known as biosimilars. The increasing trend of switching patients from effective but expensive drugs to their biosimilar counterparts will have a considerable economic impact in the coming years. However, although this will greatly extend patient access the latest treatments, clinicians, scientific societies and the patients themselves have expressed a number of concerns about their long-term efficacy and safety, as well as the consequences of potentially multiple switches being dictated by economic pressure rather than medical needs. Thee aim of this review is to evaluate the pros and cons of choosing biosimilars, and whether and when they can really be considered clinically equivalent to the original drugs.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Biosimilars
Originators
Extrapolation
Interchangeability
Switching
Megjelenés:Autoimmunity Reviews. - 18 : 12 (2019), p. 1-5. -
További szerzők:Marotto, Daniela Caporali, Roberto Galeazzi, Mauro Atzeni, Fabiola Hamar Attila Béla (1990-) (általános orvos) Soós Boglárka (1988-) (általános orvos) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

11.

001-es BibID:BIBFORM013921
Első szerző:Soltész Pál (belgyógyász, kardiológus)
Cím:Comparative assessment of vascular function in autoimmune rheumatic diseases : consideration of prevention and treatment / Soltész Pál, Kerekes György, Dér Henrietta, Szűcs Gabriella, Szántó Sándor, Kiss Emese, Bodolay Edit, Zeher Margit, Tímár Orsolya, Szodoray Péter, Szegedi Gyula, Szekanecz Zoltán
Dátum:2011
ISSN:1568-9972
Megjegyzések:Numerous autoimmune-inflammatory rheumatic diseases have been associated with accelerated atherosclerosis or other types of vasculopathy leading to increased cardio- and cerebrovascular disease risk. Traditional risk factors, as well as the role of systemic inflammation including cytokines, chemokines, proteases, autoantibodies, adhesion receptors and others have been implicated in the development of these vascular pathologies. The characteristics of vasculopathies may significantly differ depending on the underlying disease. While classical accelerated atherosclerosis has been associated with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) or spondyloarthropathies (SpA), obliterative vasculopathy may rather be characteristic for systemic sclerosis (SSc) or mixed connective tissue disease (MCTD). Antiphospholipid antibodies have been implicated in vasculopathies underlying SLE, antiphospholipid syndrome (APS), RA and MCTD. There is also heterogeneity with respect to inflammatory risk factors. Cytokines, such as tumor necrosis factor-alpha (TNF-alpha) or interleukin 6 (IL-6) and immune complexes are primarily involved in arthritides, such as RA, SpA, as well as in SLE. On the other hand, autoantibodies including anti-oxLDL anti-cardiolipin and anti-beta2GPI are rather involved in SLE- and APS-associated vasculopathies. Regarding the non-invasive assessment of vascular function, endothelial dysfunction, overt atherosclerosis and vascular stiffness may be indicated by brachial artery flow-mediated vasodilation (FMD), common carotid intima-media thickness (ccIMT) and aortic pulse-wave velocity (PWV), respectively. These abnormalities have been described in most inflammatory rheumatic diseases. While ccIMT and stiffness are relatively stable, FMD may be influenced by many confounding factors. In addition to traditional vasculoprotection, immunosuppressive agents including corticosteroids, traditional and biologic DMARDs may have significant vascular and metabolic effects. The official EULAR recommendations on the assessment and management of cardiovascular disease in arthritides have just been published, and similar recommendations in connective tissue diseases are to be developed soon.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Autoimmunity Reviews. - 10 : 7 (2011), p. 416-425. -
További szerzők:Kerekes György (1973-) (belgyógyász, kardiológus, angiológus) Dér Henrietta (1977-) (orvos) Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Szántó Sándor (1968-) (belgyógyász, reumatológus) Kiss Emese (1960-) (belgyógyász, immunológus) Bodolay Edit (1950-) (belgyógyász, allergológus és klinikai immunológus) Zeher Margit (1957-2018) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Tímár Orsolya (1980-) (belgyógyász) Szodoray Péter (1973-) (belgyógyász, orvos) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
elektronikus változat
Borító:

12.

001-es BibID:BIBFORM007083
Első szerző:Soltész Pál (belgyógyász, kardiológus)
Cím:Cardiac manifestations in antiphospholipid syndrome / Soltesz, P., Szekanecz, Z., Kiss, E., Shoenfeld, Y.
Dátum:2007
ISSN:1568-9972 (Print)
Megjegyzések:Antiphospholipid syndrome (APS) is a systemic autoimmune disease associated with arterial and venous thrombotic events and recurrent fetal loss. Cardiac manifestations in APS primarily include accelerated atherosclerosis leading to cardiovascular disease. There is increased cardiovascular mortality in APS. Cardiovascular risk is even higher in secondary APS in lupus patients. Several traditional and disease-related, autoimmune-inflammatory risk factors are involved in APS-associated atherosclerosis and its clinical manifestations. Antiphospholipid antibodies (APA), lupus anticoagulant, anti-oxLDL and other antibodies have been implicated in vascular events underlying APS. The primary and secondary prevention of atherosclerosis and CAD in these diseases includes drug treatment, such as the use of statins and aspirin, as well as lifestyle modifications. Apart from atherosclerosis and CVD, other cardiac manifestations may also be present in these patients. Among these conditions, valvular disease including thickening and vegetations is the most common. APA are involved in the pathogenesis of Libman-Sacks endocarditis usually associated with SLE. In addition, ventricular dysfunction, intracardiac thrombi and myxomas, pulmonary hypertension may also exist in APS patients. Early diagnosis of APS, thorough examination of the heart, control of traditional risk factors by lifestyle modifications and pharmacotherapy, probably anti-inflammatory treatment, and close follow-up of APS patients may help to minimize cardiovascular risk in these individuals.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Antibodies
Antiphospholipid
Antiphospholipid Syndrome
Atherosclerosis
Autoantibodies
Cardiovascular Diseases
Humans
Risk Factors
Thrombosis
Megjelenés:Autoimmunity Reviews. - 6 : 6 (2007), p. 379-386. -
További szerzők:Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Kiss Emese (1960-) (belgyógyász, immunológus) Shoenfeld, Yehuda
Internet cím:elektronikus változat
elektronikus változat
DOI
Borító:
Rekordok letöltése1 2